Evergreen Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Evergreen Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Buy	22,421 +15,814	+239%	+$866K	0.02%	450
2026 Q1	$373K	Buy	6,607 +576	+10%	+$33.6K	0.01%	981
2025 Q4	$358K	Buy	6,031 +618	+11%	+$33.6K	0.01%	935
2025 Q3	$293K	Buy	+5,413	New	+$310K	0.01%	993
2025 Q2	–	Sell	-5,028	Closed	-$355K	–	1150
2025 Q1	$355K	Buy	5,028 +1,247	+33%	+$83.9K	0.01%	661
2024 Q4	$249K	Buy	3,781 +221	+6%	+$14.8K	0.01%	843
2024 Q3	$250K	Buy	+3,560	New	+$298K	0.01%	810

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Evergreen Capital Management's BMRN Position: Q2 2026 in Review

Evergreen Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 239% in Q2 2026, buying an estimated $866K and bringing the position to 22,421 shares worth $1.28M. The position accounts for 0.02% of the portfolio, ranked #450.

Evergreen Capital Management first reported a position in BMRN in Q3 2024 and has held it in 7 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Evergreen Capital Management held 22,421 shares of BioMarin Pharmaceuticals worth $1.28M as of Q2 2026.
Evergreen Capital Management bought 15,814 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $866K.
BioMarin Pharmaceuticals made up 0.02% of Evergreen Capital Management's portfolio in Q2 2026, its #450 holding.
Evergreen Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.